Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

The FLAURA study compared osimertinib to erlotinib or gefitinib for EGFR-mutated non-small cell lung cancer patients. We've already reported the primary endpoint for the trial, which was progression-free survival, which demonstrated improvement in PFS from 10.2 months in the control group to 18.9 months with osimertinib.



Today, we report the results of overall survival, which is a secondary endpoint of the trial. What we are excited to say is that osimertinib improves overall survival for patients with EGFR-mutated disease in a clinically and statistically significant manner. The median overall survival for patients treated with osimertinib is 38.6 months, compared to 31.8 months in the control group.



This represents the first demonstration of improvement in overall survival for TKI against another in the treatment of solid tumors. This further positions osimertinib as the standard of care for frontline therapy of EGFR-mutated patients.



What are the options for patients who progress on osimertinib?

When patients experience the disease progression after osimertinib, presently the standard of care is platinum-based chemotherapy. But we're already beginning to understand the resistance mechanisms by which patients develop tumor progression on osimertinib therapy. So there are already ongoing trials with novel combination approaches, building on osimertinib to prevent or delay the emergence of resistance.



And I believe that's going to be the next wave of clinical trials, as we look at where the next set of big advances are going to come for patients with EGFR-mutated lung cancer.